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There is interest in evaluating the efficacy of lower doses of certain antiretrovirals for clinical care. We determined here the bio-
equivalence of plasma lamivudine (3TC) and intracellular 3TC-triphosphate (3TC-TP) concentrations after the administration
of two different doses. ENCORE 2 was a randomized crossover study. Subjects received 3TC at 300 and 150 mg once daily for 10
days (arm 1; n 13) or vice versa (arm 2; n 11), separated by a 10-day washout. Pharmacokinetic (PK) profiles (0 to 24 h) were
assessed on days 10 and 30. Plasma 3TC and 3TC-TP levels in peripheral bloodmononuclear cells were quantified by high-
performance liquid chromatography-tandemmass spectrometry. Within-subject changes in PK parameters (the area under the
concentration-time curve from 0 to 24 h [AUC0-24], the trough concentration of drug in plasma at 24 h [C24], and the maximum
concentration of drug in plasma [Cmax]) were evaluated by determining the geometric mean ratios (GMRs) adjusted for study
arm, period, and intra-individual variation. Regimens were considered bioequivalent if the 90% confidence interval (90% CI) fell
within the range of 0.8 to 1.25. A total of 24 subjects completed the study. The GM (90%CI) 3TC AUC0-24), expressed as ng·h/ml,
for the 300- and 150-mg doses were 8,354 (7,609 to 9,172) and 4,773 (4,408 to 5,169), respectively. Bioequivalence in 3TC PK fol-
lowing the administration of 300 and 150 mg was not demonstrated: the GMRs for AUC0-24, C24, and Cmax were 0.57 (0.55 to
0.60), 0.63 (0.59 to 0.67), and 0.56 (0.53 to 0.60), respectively. The GM (90%CI) 3TC-TP AUC0-24 values (pmol·h/106 cells) for the
300- and 150-mg doses were 59.5 (51.8 to 68.3) and 44.0 (38.0 to 51.0), respectively. Bioequivalence in 3TC-TP PK following the
administration of 300 and 150 mg was not demonstrated: the GMRs for AUC0-24, C24, and Cmax were 0.73 (0.64 to 0.83), 0.82 (0.68
to 0.99), and 0.70 (0.61 to 0.82), respectively. We found that 3TC at 150 mg is not bioequivalent to the standard regimen of 300
mg, indicating that saturation of cytosine phosphorylation pathways is not achieved at a dose of 150 mg.
Lamivudine (3TC), a commonly used nucleoside reverse trans-criptase inhibitor (NRTI), is an inactive prodrug that requires
transport into the cell and stepwise phosphorylation by intracel-
lular kinases to produce its active triphosphate form-lamivudine
triphosphate (3TC-TP) (5). The active triphosphate competes
with the corresponding endogenous nucleoside triphosphate,
dCTP, for binding to the viral reverse transcriptase. Once incor-
porated into viral DNA, chain termination results due to absence
of a 3=-hydroxy group to which 3=-5=-phosphodiester linkages are
normally made (12).
Studies conducted in HIV-infected patients have failed to es-
tablish clear pharmacokinetic-pharmacodynamic relationships
between the plasma 3TC concentrations and antiviral efficacy and
safety, whereas the concentrations of its intracellular triphos-
phate, 3TC-TP, have been shown to be the critical parameter to
predict efficacy and toxicity in vivo (1, 8).
The active nucleoside triphosphates are trapped intracellularly
due to the presence of ionic phosphate groups and this confers the
long intracellular half-lives compared to the respective parent
compounds in plasma. Since 3TC-TP is characterized by a long
intracellular half-life (ca. 15 to 16 h), active triphosphate concen-
trations persist in cells after plasma 3TC (half-life,5 h) concen-
trations have decreased, thus enabling less frequent dosing (18).
3TC is currently approved at a dose of 150mg twice daily (BID)
or 300 mg once daily (QD). During the clinical development of
3TC, no clear correlation between its dose and reductions inHIV-
RNAor other surrogatemarkers inHIV-infected individuals were
demonstrated; including in the NUCB2001 trial, at doses of 35 to
1,400 mg/day (27). The NUCA3001 (treatment naive) and
NUCA3002 (treatment experienced) trials reported no differ-
ences in reduction in HIV-RNA between patients taking 3TC at
300 mg BID versus 150 mg BID (4, 7) and, in a pharmacokinetic
substudy of NUCA3001, only small elevations in 3TC triphos-
phate concentrations were found in patients receiving the 300-mg
BID regimen (18). Similarly, a pharmacokinetic study found in-
tracellular 3TC-TP exposures to be bioequivalent at 150-mg BID
and 300-mg QD doses (28), and in a phase III (treatment naive)
trial, no differences in efficacy were reported between these regi-
mens (6). The combined data from dose-ranging and pharmaco-
kinetic studies suggest that saturation of intracellular phosphory-
lation pathways may be occurring at higher 3TC doses and, in
turn, provide an incentive to evaluate lower unit doses of 3TC.
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This study aimed to evaluate (i) the plasma and intracellular
pharmacokinetics of 3TC and its active triphosphate 3TC-TP and
(ii) the safety and tolerability of 3TC following administration of
3TC in 300-mg and 150-mg QD doses to HIV-negative healthy
volunteers.
(The results of this study were presented in part at the 12th
International Workshop on Clinical Pharmacology of HIV Ther-
apy, Miami, FL, 13 to 15 April 2011.)
MATERIALS AND METHODS
Subjects.Male and female (nonpregnant, nonlactating) subjects were el-
igible for enrolment if they provided written informed consent and met
the following criteria: age between 18 and 65 years and body mass index
(BMI) 18 to 35 kg/m2. Subjects were excluded if they had any significant
acute or chronic medical illness; abnormal physical examination, ECG or
clinical laboratory determinations; positive screen toHIVor hepatitis B or
C; current or recent (within 3 months) gastrointestinal disease; clinically
relevant alcohol or drug use that the investigator felt would adversely
affect compliance with trial procedures; exposure to any investigational
drug or placebo within 3 months of first dose of study drug; use of any
other drugs, including over-the-countermedications and herbal prepara-
tions, within 2 weeks prior to first dose of study drug; and previous allergy
to any of the constituents of the pharmaceuticals administered during the
trial.
Study design. This was a 31-day, open-label, prospective, two-arm
crossover pharmacokinetic study conducted at the Pharmacokinetic Unit
of the St. Stephen’s Centre, Chelsea and Westminster Hospital, London,
England. The study protocol was reviewed and approved by the Riverside
Research Ethics Committee (United Kingdom). All subjects provided
written informed consent and the trial was conducted in accordance with
Good Clinical Practice, the Declaration of Helsinki, and applicable regu-
latory requirements (EudraCT 2009-011844-20).
At screening, subjects had a clinical assessment and routine laboratory
investigations performed. The safety and tolerability of studymedications
were evaluated throughout the study using the NIAID Division of AIDS
table for grading the severity of adult and pediatric adverse events to
characterize abnormal findings (published December 2004), vital signs,
physical examinations, clinical laboratory investigations, and serial ECGs.
Following successful screening, subjects were randomized to (i) arm 1
and administered 3TC at 300 mg QD for 10 days (days 1 to 10), followed
by a 10-day washout period (days 11 to 20), followed by 3TC at 150 mg
QD for 10 days (days 21 to 30) or (ii) arm 2 and administered 3TC at 150
mg QD for 10 days (days 1 to 10), followed by a 10-day washout period
(days 11 to 20), followed by 3TC at 300mgQD for 10 days (days 21 to 30).
Subjects were administered study drugs in themorning within 15min
of completion of a standardized breakfast, along with 240 ml of water.
Subjects received a standardized lunch at approximately 4 h after dosing.
Pharmacokinetic sampling was performed on days 10 and 11 and days 30
and 31. Serial blood specimens for intracellular 3TC-TP and plasma 3TC
were taken at the following time points: predose (0 h) and 1, 2, 4, 8, 12, and
24 h postdose.
PBMC isolation. Blood samples for determination of intracellular
pharmacokinetic measurements in peripheral blood mononuclear cells
(PBMCs) were collected in two 8-ml cell preparation tubes (CPT; Becton
Dickinson Vacutainer) per time point. Tubes weremixed gently by inver-
sion until centrifugation at room temperature (20°C) for 20 min at 1,600
relative centrifugal force (RCF). After centrifugation, the upper layers of
plasma and PBMCs were gently mixed and transferred from both CPT to
a single graduated 50-ml conical tube. Isotonic saline (0.9%)was added to
bring the volume to exactly 30 ml. The sample was then gently mixed by
inversion, and a 40-l aliquot was taken for initial cell counting (Digital
Bio Adam Microchip Automatic Cell Counter; NanoEnTek, Inc., Seoul,
Korea). The count was multiplied by 30 to calculate the total number of
cells in 30 ml and recorded. The samples were centrifuged for 15 min at
400 RCF to pellet the cells, and the supernatant was removed. The cell
pellet was suspended in 1 ml of 70% methanol, vortexed (3 to 5 min) to
ensure cell lysis, and stored at80°C. Samples were shipped on dry ice to
the Liverpool Biomedical Research Centre Bioanalytical Facility (GCLP
accredited) for liquid chromatography-tandem mass spectrometry (LC-
MS/MS) analysis.
Analytical methods. (i) Quantification of lamivudine from plasma.
Plasma 3TC concentrations were quantified by a validated solid-phase
extraction (SPE) method coupled with reversed-phase high-performance
liquid chromatography–tandem mass spectrometry (HPLC-MS/MS).
Plasma samples (300l) were prepared in formic acid (300l; 0.02%)
containing an internal standard, 2-chloroadenosine (Cl-A; 5 g/ml; 20
l), and loaded onto a 100-mg SPE BondElut C18 column (Varian, Inc.,
Netherlands). Columns were conditioned with methanol (1 ml) and
0.02% formic acid (1 ml; pH 3). Samples (400 l) were loaded onto the
column and rinsed with 0.02% formic acid (200l). Analytes were eluted
with methanol (100l), evaporated to dryness, reconstituted in 100l of
mobile phase, and injected (10 l) onto the HPLC column.
Chromatography was performed on a Synergi polar C18 column (4
m, 150mmby 2.0mm; Phenomenex, Cheshire, United Kingdom).Mo-
bile phase A consisted of 0.1% formic acid in water, and mobile phase B
consisted of 0.1% formic acid in acetonitrile (ACN). Initial conditions
consisted of 99% mobile phase A, increasing in organic content to 40%
mobile phase B in 0.7 minmaintained over 1.3 min and equilibrated back
to the initial conditions over a total run time of 6 min. The flow rate was
400 l/min. The triple-quadrupole mass spectrometer (TSQ Quantum
Access; Thermo Electron Corp., Hemel Hempstead, United Kingdom)
was operated in positive ionization mode, and detection and quantifica-
tion was performed using multiple reaction monitoring (MRM).
The assay was validated over a calibration range of 6.9 to 5,137 ng/ml.
The interday precision (percent coefficient of variation [CV%]) based on
quality control (QC) samples was between 3.9 and 6.8%, and accuracy
(percent bias) was11.6%. The percentage recovery was90%.
(ii) Quantification of intracellular lamivudine-triphosphate from
PBMC. Intracellular 3TC-TP concentrations were quantified from hu-
man PBMC using a validated ion-pair reversed-phase HPLC-MS/MS
method. 3TC-TP [()--L-2=,3=-dideoxy-3=-thiacytidine triphosphate]
was purchased from Moravek Biochemicals (Brea, CA), and an internal
standard 2-chloroadenosine 5=-triphosphate (Cl-ATP) was purchased
from Sigma-Aldrich, United Kingdom.
Blank human PBMCs were isolated from drug-free human buffy coat
via density gradient centrifugation. The cells were prepared in 70%meth-
anol and dispatched in fractions of approximately 2 106 cells. Calibra-
tors/QCwere prepared frommaster stock solutions (1mg/ml in ultrapure
water). A master stock solution of Cl-ATP was prepared identically in
water. All stock solutions were stored at 80°C. Stock solutions were
further diluted with PBMC lysate (2 106 cells in 70%methanol) to yield
working solutions containing 3TC-TP, which were then dispensed (1 ml)
into labeled screw-cap tubes and stored at 80°C until use. A working
internal standard solution was prepared by dilution of Cl-ATP to 4g/ml
and stored at40°C.
On the day of analysis, 1 ml of LC-MS-grade ACN was added to the
calibrators/QC and clinical samples. Samples were vortexed and centri-
fuged (13,000 rpm, 4°C), and the supernatant was transferred to fresh
glass tubes. Cl-ATP (20 l; 4 g/ml) was added, and the samples were
evaporated to dryness with a nitrogen stream evaporator (20°C). The
samples were then resuspended in 100 l of 5 mM ammonium formate
and 50mMN,N-dimethylhexylamine (DMHA) at 1:1 (vol/vol). Sufficient
sample was transferred into autosampler vials ready for injection (25 l)
onto the HPLC column.
Analytes were eluted using a Fortis C18 column (3m, 150 by 2.1mm;
Fortis Technologies, Ltd., Cheshire, United Kingdom). Mobile phase A
(pH8.6) consisted ofDMHA(5mM) and 10mMammonium formate–
water (1:1 [vol/vol]), andmobile phase B consisted ofDMHA(5mM) and
10mM ammonium formate–ACN (1:1 [vol/vol]). Initial conditions con-
sisted of 90% mobile phase A, increasing in organic content to 50% mo-
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bile phase B in 11.2 min (maintained for 2 min). The column was equili-
brated back to the initial conditions over a total run time of 19 min. The
flow rate was set at 350l/min. The triple-quadrupole mass spectrometer
(TSQ Quantum Access) was operated in negative ionization mode, and
detection and quantification was performed using MRM.
The assay was validated over a calibration range of 1.5 to 100 ng/
sample (ca. 2- to 200 pmol). The interday precision of QC samples was
between 7.7 to 11%, and the % bias was2.0% (2 to 85 ng/sample). The
percentage recovery was80%.
(iii) Pharmacokinetic and statistical analysis. The pharmacokinetic
parameters for the 3TC and 3TC-TPmaximum concentration (Cmax), the
time to Cmax (Tmax), and the trough concentrations at 0 and 24 h (C0 and
C24) were derived from the concentration-time profiles. The area under
the curve concentration-time curve from 0 to 24 h (AUC0-24) and the
elimination half-life (t1/2) were calculated using WinNonlin software
(version 6.1; Pharsight Corp., Mountain View, CA). Pharmacokinetic pa-
rameters were expressed as unadjusted geometric means (GM) and asso-
ciated 90% confidence intervals (90% CI). Inter-individual variability in
plasma concentrations was assessed by measuring the coefficient of vari-
ation [CV (standard deviation/mean) 100].
Within-subject changes of drug concentrations were assessed by geo-
metric mean ratios (GMRs) and associated 90% CI (using a 3TC 300-mg
QDdose as the reference group) after adjustment for the study arm, treat-
ment period (day 10 or 30), and crossover design (intra-individual varia-
tion) using linear mixed-effects modeling (SAS; version 9.1). A basic
mixed model was also fitted (correcting only for crossover design) and
used as a reference in determining the clinical importance of differences
between study arms or treatment period. The results were considered
statistically significant at  0.10 or if the 90% CI of the GMR excluded
1. No adjustments were made for multiple comparisons. 3TC doses were
considered bioequivalent if the 90%CI for the GMR fell within the accep-
tance range of 0.8 to 1.25.
RESULTS
Demographic and clinical characteristics. Twenty-four subjects
(13 [54%] female) completed the study, which included 13 sub-
jects in arm 1 (10 female) and 11 subjects (3 female) in arm 2. The
median (range) age, weight, and body mass index (BMI) were 34
(27 to 57) years, 72 (49 to 110) kg, and 24 (20 to 35) kg/m2,
respectively. Sixteen subjects wereCaucasian, fourwere black, one
was of Asian origin, and three defined themselves as “other” (not
specified). The study drugs were well tolerated, and no grade 3 or
4 adverse events were reported. Lipid, total cholesterol, and tri-
glyceride levels were normal at screening and at days 37 to 44
follow-up.
Plasma lamivudine pharmacokinetics. The plasma 3TC
pharmacokinetic parameters for all 24 study participants (arm 1
and arm 2) are presented in Table 1, and the pharmacokinetic
profiles over 24 h are illustrated in Fig. 1, respectively. The elimi-
nation half-life did not differ between the two doses. Bioequiva-
lence in plasma 3TC pharmacokinetic parameters, following
300-mg and 150-mg QD regimens, was not demonstrated as the
GMR (90% CI) were 0.57 (0.55 to 0.60) for AUC24, 0.63 (0.59 to
0.67) for C24, and 0.56 (0.53 to 0.60) for Cmax.
Statistically significant differences in 3TC plasma concentra-
tionswere observed between the two study arms (data not shown),
inwhich participants in arm1 had, on average, higher 3TCplasma
exposures than participants in arm 2, independent of the dosing
regimen or treatment period. However, despite these differences,
the study arm had very little influence on the overall effect of dose
upon 3TC pharmacokinetic outcomes. When we compared the
full mixedmodel to the basicmixedmodel (Table 1), almost iden-
tical GMR estimates of the effect of dose were evident, indepen-
dent of the study arm.
Intracellular lamivudine triphosphate pharmacokinetics.
Intracellular 3TC-TP pharmacokinetic parameters are presented
in Table 2, and the pharmacokinetic profiles are reported in Fig. 2.
The GM (90% CI) intracellular 3TC-TP AUC24 (pmol.h/106
cells), C24, and Cmax (pmol/106 cells) for the 300-mg dose were
59.5 (51.8 to 68.3), 1.49 (1.19 to 1.86), and 4.10 (3.59 to 4.69),
respectively. For the 150-mg dose, they were 44.0 (38.0 to 51.0),
1.23 (1.00 to 1.52), and 2.95 (2.47 to 3.51), respectively. Bio-
equivalence in intracellular 3TC-TPpharmacokinetic parameters,
TABLE 1 Geometric mean plasma 3TC pharmacokinetic parameters during 3TC 300-mg and 150-mg regimensa
Parameter QD dose (mg)
Geometric mean
(90% CI)
Full mixed model
Basic mixed
model
Dose Arm Period Dose
GMR (90% CI) P P P GMR (90% CI)
AUC0-24 (ng · h/ml) 150 4,773 (4,408–5,169) 0.57 (0.55–0.60) <0.001 0.002 0.277 0.57 (0.56–0.59)
300 8,354 (7,609–9,172)
C24 (ng/ml) 150 38.1 (34.0–42.7) 0.63 (0.59–0.67) <0.001 0.105 0.955 0.63 (0.59–0.67)
300 60.8 (53.4–69.2)
C0 (ng/ml) 150 39.4 (34.1–45.5) 0.64 (0.58–0.70) <0.001 0.040 0.416 0.64 (0.59–0.71)
300 61.3 (52.6–71.3)
Cmax (ng/ml) 150 757 (688–833) 0.56 (0.53–0.60) <0.001 0.019 0.558 0.56 (0.53–0.60)
300 1,344 (1,247–1,448)
t1/2 (h) 150 5.91 (5.63–6.19) 1.03 (0.99–1.08) 0.186 0.315 0.807 1.12 (0.96–1.32)
300 5.71 (5.50–5.94)
Tmax (h) 150 1.73 (1.50–2.00) 1.15 (1.00–1.32) 0.107 0.851 0.004 1.12 (0.96–1.32)
300 1.54 (1.34–1.77)
a GMRs were calculated using 3TC at 300 mg as the referent group. A full mixed model (fitting dose, study arm, and treatment period with adjustment for crossover) and a basic
mixed model (fitting dose with adjustment for crossover) were utilized. Statistically significant P values are indicated in boldface.
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following 300-mg and 150-mg QD regimens, was not demon-
strated since the GMRs (90% CI) were 0.73 (0.64 to 0.83) for
AUC24, 0.82 (0.68 to 0.99) forC24, and 0.70 (0.61 to 0.82) forCmax.
Although subjects received timed and witnessed drug doses
after a standardized meal on the pharmacokinetic study days, the
interpatient variability of 3TC-TP AUC24, C24, and Cmax values
ranged between 36 and 62%. Plasma 3TC and intracellular
3TC-TP concentrations (n 24)were not significantly correlated.
A significant effect of treatment period on intracellular drug
exposure was observed. 3TC-TP exposures were, on average,
higher at day 30 than at day 10, independent of dose and of study
arm (P  0.008). Similar statistically significant differences were
also observed for C0 (P 0.007) and Cmax (P 0.008). However,
despite being a statistically significant predictor, treatment period
had very little impact on the observed relationship between dose
and pharmacokinetic outcomes. When we compared the full
mixed model to the basic mixed model, independent of adjust-
ment for differences in treatment period, we obtained comparable
GMR estimates of the dose effect.
Interestingly, whendatawere stratified according to study arm,
FIG 1 Steady-state plasma 3TC geometric mean (90% CI) concentrations over 24 h during 300-mg and 150-mg intakes (n 24). Solid black diamonds, 3TC
300-mg QD regimen; gray triangles, 3TC 150-mg QD regimen; dashed lines, 90% CI.
TABLE 2 Intracellular 3TC-TP pharmacokinetic parameters during 3TC 300-mg and 150-mg regimensa
Parameter QD dose (mg)
Geometric
mean (90% CI)
Full mixed model
Basic mixed
model
Dose Arm Period Dose
GMR (90% CI) P P P GMR (90% CI)
AUC0-24 (pmol · h/106 cells) 150 44.0 (38.0–51.0) 0.73 (0.64–0.83 <0.001 0.637 0.008 0.74 (0.64–0.86)
300 59.5 (51.8–68.3)
C24 (pmol/106 cells) 150 1.23 (1.00–1.52) 0.82 (0.68–0.99) 0.083 0.404 0.246 0.83 (0.68–1.01)
300 1.49 (1.19–1.86)
C0 (pmol/106 cells) 150 1.41 (1.14–1.74) 0.74 (0.61–0.90) 0.012 0.796 0.007 0.76 (0.61–0.95)
300 1.84 (1.52–2.22)
Cmax (pmol/106 cells) 150 2.95 (2.47–3.51) 0.70 (0.61–0.82) <0.001 0.981 0.008 0.72 (0.61–0.85)
300 4.10 (3.59–4.69)
Tmax (h) 150 5.11 (3.80–6.87) 1.01 (0.72–1.43) 0.944 0.013 0.027 0.98 (0.68–1.41)
300 5.24 (3.98–6.90)
a GMRs were calculated using 3TC at 300 mg as the referent group. A full mixed model (fitting dose, study arm, and treatment period with adjustment for crossover) and a basic
mixed model (fitting dose with adjustment for crossover) were utilized. Statistically significant P values are indicated in boldface.
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no significant differences were observed in 3TC-TP exposures
(AUC24) between the 3TC 300-mg and 150-mg dosing in arm 1,
when 300-mg dosing preceded 150-mg dosing (the AUC24 values
were 52.3 and 47.5 pmol·h/106 cells, respectively [P  0.374]),
whereas a significant difference (P  0.001) was seen when we
compared the 3TC-TP AUC24 in arm 2 when 150-mg dosing pre-
ceded 300-mg dosing (the AUC24 values were 40.5 and 69.2
pmol·h/106 cells, respectively).
DISCUSSION
This study investigated the steady-state pharmacokinetics of 3TC
when administered at 150 mg and 300 mg QD to healthy HIV-
negative volunteers. Both plasma 3TC concentrations and intra-
cellular 3TC-TP concentrations were measured. A study popula-
tion consisting of healthy subjects was deemed appropriate, since
there are no reports of differences in 3TC pharmacokinetics be-
tween healthy and HIV-infected populations (19, 20, 28). Impor-
tantly, it is not possible to conduct a study with monotherapy
lamivudine in HIV-infected subjects because of the high likeli-
hood of HIV drug resistance in this setting.
Administration of different 3TC doses resulted in significantly
lower plasma 3TC and intracellular 3TC-TP pharmacokinetic pa-
rameters during intake of 150 mg QD. Consequently, bioequiva-
lence between low dose 3TC at 150 mg QD and the standard
300-mg QD regimen was not achieved. Both doses were well tol-
erated, and no unexpected or serious adverse events related to the
studymedicationwere reported. The steady-state plasma 3TC and
intracellular 3TC-TP pharmacokinetic parameters observed in
the present study with 300 mg QD were comparable to that pre-
viously reported in healthy volunteers (2, 3, 28) andHIV-infected
patients (2, 9, 14, 17, 18, 21) receiving 3TC doses at 300mgQD or
150mg BID. However, there was marked intersubject variation in
3TC-TP concentrations, both here and in previous studies (the
CV% invariably exceeded 50%), and differences between study
centers, with some reporting slightly higher 3TC-TP concentra-
tions (6 to 11 pmol/106 cells) in HIV-infected patients (13, 21).
Such variability in nucleoside triphosphate concentrationsmay be
attributed to a number of interrelated factors that relate to the
patient/host (immune status, cellular function, and genetic varia-
tion) intracellular pharmacokinetics (endogenous enzyme activ-
ity, competition with endogenous deoxynucleoside triphos-
phates, and concomitantly administered drugs) and differences in
bioanalytical methods. For example, some centers analyze nucle-
oside triphosphates indirectly by separating the intracellular
nucleotides using solid-phase extraction (SPE), followed by
enzymatic dephosphorylation, desalting, and quantification by
HPLC-MS/MS (16, 23). Others analyzed the nucleoside triphos-
phates directly via HPLC-MS/MS without dephosphorylation.
However, due to the chemical similarity and high polarity of the
endogenous and NRTI triphosphates, which cannot be easily re-
tained via conventional reversed-phase chromatography, most
methods have been developed using weak anion-exchange chro-
matography (24) or ion-pair reversed-phase chromatography (10,
22). There is currently no external QA scheme for nucleoside
triphosphates.
Significant differences in plasma 3TC pharmacokinetics were
observed between the two study arms. Given that arm 1 contained
a higher proportion of females than arm 2 (76% versus 27%),
differences in pharmacokinetic outcomes between the arms could
potentially be gender related. This was confirmed through a sec-
ondary analysis in which gender was included into the full mixed
model (data not shown). Including gender transferred much of
the statistical significance of the difference in 3TC plasma AUC24
and Cmax from study arm (P 0.06 and P 0.38 when gender is
FIG2 Steady-state intracellular 3TC-TP geometricmean (90%CI) concentrations over 24 h during 300-mg and 150-mg intakes (n 24). Solid black diamonds,
3TC 300-mg QD regimen; gray triangles, 3TC 150-mg QD regimen; dashed lines, 90% CI.
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included) to gender (P  0.06 and P  0.002). However, the
present investigation was neither designed nor powered to prop-
erly investigate gender effects. For example, given that both
300-mg and 150-mg doses were taken by all 24 participants and
within each treatment period, adjusting for gender has, by defini-
tion, no impact on the observed results for either dose or treat-
ment period.
There is currently no evidence in the literature to suggest
gender-related differences in 3TC pharmacokinetics when nor-
malized for body weight (26). Gender-related differences in intra-
cellular 3TC-TP pharmacokinetics have been reported previously,
with most, but by no means all (2), studies observing a trend
toward elevated TP concentrations in females (1, 21). Similar
findings have been reported for zidovudine-TP (1, 25),
tenofovir-DP (21), and carbovir-TP (11). No gender-related dif-
ferences in intracellular 3TC-TP pharmacokinetics were observed
in the present study (P 0.20).
There were smaller differences in the pharmacokinetics of in-
tracellular 3TC-TP between the two dosing regimens than in
plasma. The intracellular 3TC-TP C24 and AUC24 were, on aver-
age, only 17 and 26% lower, respectively, with the 150-mg QD
dose. One explanation is that saturation of the enzymatic conver-
sion of 3TC-diphosphate (3TC-DP; the predominant anabolite
and the rate-limiting step in the 3TCphosphorylation pathway) to
3TC-TPmay occur at higher 3TCdoses, resulting in pooling of the
intermediate DP and continual persistence of the active TP over
the course of the dosing interval, despite rapidly declining 3TC
systemic concentrations (15).
Indeed, an apparent effect of treatment period upon 3TC-TP
pharmacokinetics was observed. Higher 3TC-TP exposures were
present at day 30 compared to day 10, suggesting there may be
incomplete washout of the TP (or DP) anabolites during days 11
to 20 or changes to 3TC phosphorylation patterns over the dura-
tion of treatment. Sequestration inside the cell may also explain
why there is little association between intracellular 3TC-TP and
plasma 3TC concentrations. In the present study, the geometric
mean elimination t1/2 of 3TC-TP were 16.6 and 20.9 h, for the
300-mg and 150-mgQDdoses, respectively.Moore et al. reported
a 3TC-TP t1/2 of ca. 15 to 16 h (based data derived from 12-h
pharmacokinetic profiles, after 3TC300-mg and 150-mgBIDdos-
ing) (18); however, these values could be seen as an underestima-
tion of the “true” terminal elimination t1/2 and persistence of the
anabolite(s) beyond the dosing interval. Indeed, there are reports
of up to a 3-fold accumulation of 3TC-TP over the course of 12
days (2).
In conclusion, these pharmacokinetic data show that 3TC at
150 mg is not bioequivalent to the standard regimen of 300 mg
once daily. Although we do not know a definitive threshold of
3TC-TP to predict efficacy, and it cannot be ruled out that a lower
dosemay give a concentration on the plateau of the concentration
effect curve, we consider that future evaluation of the lower dose is
not warranted based on these data.
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